Foundation Medicine (FMI): New Pick Added To Raygent Core Portfolio

Foundation Medicine (FMI) New Pick at $20.40

We have added Foundation Medicine (FMI) to our core portfolio because of their leadership position in pharmacogenomics and molecular medicine for cancer care. The Foundation One genomic profile helps physicians make treatment decisions for patients with cancer by identifying the molecular growth drivers of their cancers and helping oncologists match this with relevant targeted treatment options. Foundation Medicine is a long term growth prospect with the largest genomic database in oncology.

The Company announced today release of molecular information to NCI in support of Precision Medicine initiatives.

Market Cap $691

Q1 Revenues $30.378M, loss (17.3M). Q/Q Sales Increase 57.5%.

Cash and Investments ~$210M

Roche Holdings Inc. shares held 20.6M

Disclosure long FMI

Update later after close.

 

, , , ,

No comments yet.

Leave a Reply